Skip to content
DataLookout
Menu

NCT01088789

Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer

StatusCompleted
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 29 versions: 17 with changes below, 12 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 20 words
    • Trial completed
    • Study completion date changed from estimate of Aug 2026 to Mar 2, 2026
    • Secondary endpoints: 2 to 4
  2. Minor Study completion date: Aug 2025 to Aug 2026v28
  3. Minor Study completion date: Jul 2025 to Aug 2025v27
  4. Notable Results first posted: Jul 3, 2025v26 Show 6 more changesShow less
    • Primary endpoints: 1 to 2
    • Interventions: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine. (Biological) to Cyclophosphamide (Drug), Cyclophosphamide Pill (Drug), GVAX Pancreas Vaccine (Biological)
    • Secondary endpoints expanded, about 7 words
    • Study description shortened, about 117 words
    • Study arms: 5 to 7
    • Study title expanded, about 3 words
  5. Minor Primary completion date changed from estimate of Aug 2024 to Jul 17, 2024
    • Study completion date: Aug 2024 to Jul 2025
    v23
Show 11 earlier versionsHide 11 earlier versions
  1. Notable Primary and study completion dates: Aug 2023 to Aug 2024v22
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 72 to confirmed 71
    • Primary and study completion dates: Apr 2023 to Aug 2023
    • Site details revised
    v21
  3. Notable Eligibility criteria shortened, about 51 words
    • Study description shortened, about 267 words
    • Study arms: 3 to 5
    v20
  4. Minor Study description expanded, about 5 wordsv17
  5. Minor Start date: Apr 2010 to Apr 20, 2010
    • Collaborators expanded, about 4 words
    v16
  6. Notable Eligibility criteria expanded, about 3 wordsv12
  7. Minor Enrollment target: 58 to 72v8
  8. Notable Trial status: Active, Not Recruiting to Recruiting
    • Site details revised
    v7
  9. Minor Trial status: Recruiting to Active, Not Recruiting
    • Study site revised
    v5
  10. Notable Enrollment target: 20 to 58
    • Eligibility criteria expanded, about 42 words
    • Study description expanded, about 55 words
    v4
  11. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v3
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Participants Experiencing Drug-Related Adverse Events (AEs) Requiring Treatment Discontinuation
Timeframe: 129 Months
Number of Participants Experiencing Grade 3 or Above Drug-Related Adverse Events (AEs)
Timeframe: 129 months

Secondary (4)

Disease Free Survival (DFS) From Surgery
Overall Survival (OS) From Surgery
Disease Free Survival (DFS) From First Dose of Study Drug
Overall Survival (OS) From First Dose of Study Drug

Arms and interventions

Cohort 1 (J0810 Arm A)Experimental

Patients coming from J0810 (NCT00727441). Patients receive GVAX.

Cohort 1 (J0810 Arm B)Experimental

Patients coming from J0810 (NCT00727441). Patients receive IV CY and GVAX.

Cohort 1 (J0810 Arm C)Experimental

Patients coming from J0810 (NCT00727441). Patients receive oral CY and GVAX.

Cohort 2 (Vaccine Naive)Experimental

Patients receive IV CY and GVAX.

Cohort 3 (J1568)Experimental

Patients coming from J1568 (NCT02451982). Patients receive IV CY and GVAX.

Cohort 4 (J15237)Experimental

Patients coming from J15237 (NCT02648282). Patients receive IV CY and GVAX.

Cohort 5 (J1766)Experimental

Patients coming from J1766 (NCT03153410). Patients receive IV CY and GVAX.

Drugs: Cyclophosphamide, Cyclophosphamide Pill

Biologicals: GVAX Pancreas Vaccine

Sites

1 site in 1 country

  • Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimore, Maryland, United States